PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables. Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene ...

● . ● Torex Gold Reports Q2 2024 Results Another consistent quarter of safe and reliable production; on track to deliver on full-year operational guidance August 07, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - August 7, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and six months ended June 30, 2024. Torex ...

In its upcoming report, 10x Genomics (TXG) is predicted by Wall Street analysts to post quarterly loss of $0.47 per share, reflecting an increase of 11.3% compared to the same period last year. Revenues are forecasted to be $150.9 million, representing a year-over-year increase of 2.8%. The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial ...

Wall Street expects a year-over-year increase in earnings on higher revenues when 10x Genomics (TXG) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better than expec ...

● Torex Gold Provides Q2 2024 Update on Media Luna Project (All amounts expressed in U.S. dollars unless otherwise stated) "Development of Media Luna continues to track to schedule, with first production of copper concentrate anticipated by year end and commercial production expected in Q1 2025. As at the end of June, Media Luna was 78% complete across engineering, procurement, underground development/construction, and surface construction, compared to 69% at the end of March. "With completion of Media Luna ...

Why TXG Could Witness a Solid Upside Here's What You Should Know About Analysts' Price Targets The average comprises 16 short-term price targets ranging from a low of $16 to a high of $55, with a standard deviation of $12.57. While the lowest estimate indicates a decline of 20% from the current price level, the most optimistic estimate points to a 175% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard d ...

Company Overview - 10x Genomics experienced a significant stock price increase of 8.2%, closing at $16.99, driven by investor optimism following the announcement of its Xenium In Situ platform's use in a study published in the Journal of Dental Research [1][4] - The company is set to report its second-quarter 2024 financial results on August 8, with revenue and earnings expected to grow by 3.1% and 13.2% respectively [1][5] Financial Performance Expectations - The consensus estimate for 10x Genomics' upcoming quarterly loss is projected at $0.46 per share, reflecting a year-over-year change of +13.2% [5] - Revenue expectations for the quarter stand at $151.42 million, which is an increase of 3.1% compared to the same quarter last year [5] Market Position and Trends - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting stability in earnings expectations [6] - 10x Genomics is part of the Zacks Medical Info Systems industry, which includes other companies like Azenta (AZTA), which saw a 4.5% increase in its stock price recently [7]

Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event. Disclosure Information SOURCE 10x Genomics, Inc. PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thur ...

Torex Gold Reports Positive Results from the 2024 ELG Underground Drilling Program June 27, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ongoing drilling program at El Limón Guajes ("ELG") Underground. The results to date support Torex's target of extending the mine life of ELG Underground beyond 2028 by identifying new zones of higher-grade ...

Core Insights - 10x Genomics' Xenium In Situ platform was utilized in a study published in the Journal of Dental Research, providing new insights into the cellular mechanisms involved in secondary palate formation [1][2] - The study highlights the role of the Pax9 protein as a transcription factor in Wnt signaling, which is crucial for embryonic development [2][3] Company Overview - 10x Genomics is a leader in single cell and spatial biology, offering integrated solutions that include instruments, consumables, and software to enhance biological research [8][9] - The company's products are instrumental in advancing research across various fields, including oncology, immunology, and neuroscience, contributing to significant breakthroughs in understanding health and disease [9] Research Findings - The study revealed that the Xenium platform allowed for higher spatial resolution in gene expression analysis, enhancing the understanding of signaling pathways in palate development [3][4] - Researchers found significant differences in spatial gene expression between wild-type and Pax9-deficient mice, indicating Pax9's role in progenitor cell differentiation and maturation [6][7] - The analysis suggested that disrupted Wnt signaling due to loss of Pax9 expression affects proper bone formation, which could lead to potential therapeutic strategies for cleft palate anomalies [4][6]